Petri Dish Market Trends, and Forecast to 2026

Petri dish also called as cell culture dishes is common glassware used in research and academic laboratories and hospital in order to hold, transfer, and incubate the sample substance under study. Glass petri dish has lid over it and it majorly used to hold the culture medium of Agar on which bacteria, fungus, and virus are grown, which can be studied for various purpose. Petri dish prevents culturing microorganisms while separating them from airborne contaminates. Petri dish is significant Labware in almost all research efforts, in addition many infectious disease are diagnosed with culture medium method that utilizes petri dish. Majorly glass petri dish are used for various experimental activities. However, polystyrene plastic petri dish are also used according to sample need, as some samples are incompatible or react with glass material.

Increasing research and development in the field of proteomics and genomics and high prevalence of infectious disease and cancer are the major factors driving growth of the petri dish market. For instance, According to report by the International Federation of Pharmaceutical Manufacturer and Association report published in 2017, pharmaceutical industry invests US$ 149.8 billion on research and development annually. There are more than 7000 compounds in preclinical stage of development as per same source.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1978 

High prevalence of infectious disease urinary tract infection, Tuberculosis (TB), Ebola, Sexually Transmitted Disease, and respiratory disease worldwide are expected to drive petri dish market growth. According to World Health Organization (WHO) factsheet in February 2018, in 2016, around 10.4 million people suffered from TB and 1.7 million died from the disease (including 0.4 million among people with HIV). According to same source, Over 95% of TB deaths were reported in low- and middle-income economies. Petri dish based culture medium test are carried out to confirm the presence of disease, which is expected to drive petri dish market growth.

Furthermore, according to 2012, EU Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world. Petri dish market is an essential part of any research efforts, which is expected to witness major traction due to increasing research activities by commercial companies and research institutes.

However, Petri dish market is been in mature stage for long with less of innovation and no new introduction from key players. Non culture based diagnostic test are rapidly emerging in the market, which offer fast and reliable results as compared to culture based test that rely on petri dish, which in turn is expected to restrain growth of the market. Furthermore, adoption of the automated liquid handling system and other lab automation tools by large research laboratories may hinder growth of the petri dish market. Various small scale manufacturers in emerging economies create strong competition in petri dish market and also makes petri dish market fragmented.

There is high prevalence of chronic disease such as cancer, cardio vascular disease, and diabetes worldwide, research efforts in developed region has been diverted to personalized medicine to cure this disease. Petri dish market would be supported due to this efforts in finding effective treatment avenues for this disease. Personalized medicine use tools of genomics, proteomics, and cell-based therapies to effectively target disease resulting in greater chance of survival of patient. Petri dish is essential part of most of this process such as cell isolation and cell culture growth. Well established healthcare infrastructure coupled with high adoption rate of new technology for the treatment of cancer in the developed region is expected to boost overall sales of petri dish in regions such as North America and Europe. There are over 200 companies engaged in development of personalized cell therapy products in the U.S. alone

In 2017, the FDA approved 2 CAR-T cell therapy for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia and adult patients with certain types of large B-cell lymphoma. Such advancement in cell-based therapy needs extensive utilization of petri dish, which is expected to fuel petri dish market growth.

Key Vendors:

Aicor Medical, NEST Biotechnology, Thermo Fisher Scientific, Greiner Bio-One, Corning, Phoenix Biomedical, Millipore Sigma, Reinnervate, Narang Medical Limited, Biosigma S.r.l., Pall Corporation



Show full profile

Basic Member

Reset Password